## 56th SSRMP Annual Meeting



Contribution ID: 25

Type: Oral

## Modelling the biological effect of temporally feathered radiotherapy

Thursday 30 November 2023 13:10 (10 minutes)

Purpose: Temporally feathered radiotherapy (TFRT) replaces a standard treatment plan by 5 iso-curative sub-plans (López Alfonso et al. Med Phys 2018). Each sub-plan is created such that one of five chosen organsat-risk (OARs) receives a higher dose compared to the standard plan in one fraction, allowing the other four OARs to receive a lower dose. Each OAR then receives one high and four low doses in alternation, weekly. There are two potential benefits. First, TFRT can deliver a lower total physical dose to the feathered OARs by distributing the dose on different days. Second, a time-dependent normal tissue complication probability (NTCP) model suggests that the damage caused by the high dose is offset by increased repair during the low doses. However, the radiosensitivity parameters  $\alpha$ ,  $\beta$ , and recovery rate  $\mu$ , needed for NTCP calculation are not well defined for OARs.

We investigate the potential benefit of TFRT for ranges of  $\alpha$ ,  $\beta$ , and  $\mu$ , independently of the physical dose reduction effect.

Methods: We calculate OAR toxicity for a treatment delivering 2 Gy to the tumour in 25 fractions and a dose ds to the OAR in a standard fractionation. With TFRT, the high and low doses are ds + 0.4 Gy and ds –0.1 Gy respectively so the total physical dose is the same as in the standard plan. Toxicity is calculated for ranges of  $\alpha$  (0.05-1.00 1/Gy),  $\mu$  (0.05-0.50 1/day) and ds (0.1-2.0 Gy), with  $\beta$  such that  $\alpha/\beta$  = 3 Gy (constant).

Result: The OAR toxicity reduction from TFRT for the investigated values is at the maximum  $\alpha = 1.0 \text{ 1/Gy}$ , the minimum  $\mu = 0.05 \text{ 1/day}$  and for ds = 0.3 Gy with a toxicity reduction of 11%-points. Of the investigated combinations, 14% reach a toxicity reduction of at least 1%-point and none have a negative effect for TFRT. Conclusion: TFRT can reduce OAR toxicity compared to standard fractionation with the same total physical dose. However, radiobiological parameters must be determined.

Supported by Varian Medical Systems.

**Primary authors:** HOSIE, Daniel (ETH Zurich); BERTHOLET, Jenny (Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland); STAMPANONI, Marco F. M. (Institute for Biomedical Engineering, ETH Zürich and PSI, Villigen, Switzerland); FIX, Michael; MANSER, Peter (Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, and University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, And University of Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, Bern University Hospital, Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern University Hospital, Bern, Bern, Bern, Switzerland); State of Radiation Oncology, Inselspital, Bern, Bern,

Presenter: HOSIE, Daniel (ETH Zurich)

Session Classification: Session II

Track Classification: Radiation Therapy